Recent Updates on Glucagon-Like Peptide 1 Receptor Agonist / 임상당뇨병
Journal of Korean Diabetes
;
: 126-133, 2021.
Article
in Korean
| WPRIM
| ID: wpr-918911
ABSTRACT
Glucagon-like peptide 1 (GLP-1) is a peptide hormone secreted by L cells of the small intestine in response to nutrients. GLP-1 presents a glucose-lowering effect via insulinotropic action on pancreatic β-cells. In addition to the insulinotropic effect, GLP-1 has pleiotropic actions associated with clinical benefits. GLP-1 receptor agonists (GLP-1RAs) are a well-established effective treatment for patients with type 2 diabetes mellitus (T2DM). GLP-1RAs have antihyperglycemic effects and help reduce glucose levels and body weight, with a low risk of hypoglycemia. Additionally, GLP-1RAs have beneficial effects on cardiovascular risk factors, such as blood pressure and lipid levels. Large randomized cardiovascular outcome trials and meta-analyses have demonstrated that GLP-1RAs reduce cardiovascular disease in T2DM patients. GLP-1RAs are recommended as part of glucose-lowering regimens in patients with T2DM and established cardiovascular disease or those at high risk. Renal protective effects and beneficial effects of GLP-1RAs on non-alcoholic fatty liver disease have been suggested.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Controlled clinical trial
Language:
Korean
Journal:
Journal of Korean Diabetes
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS